SSG
CGON icon

Summit Securities Group’s CG Oncology CGON Stock Holding History

Summit Securities Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.3K Buy
+976
New +$63.8K 0.01% 510
2025
Q2 		– Sell
-163
Closed -$3.99K – 1125
2025
Q1 		$3.99K Buy
+163
New +$4.58K ﹤0.01% 627

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Securities Group's CGON Position: Q2 2026 in Review

Summit Securities Group opened a new position in CG Oncology (CGON) in Q2 2026: 976 shares worth $69.3K. The stake represents 0.01% of the portfolio and ranks #510 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in CGON as recently as Q1 2025.

Summit Securities Group first reported a position in CGON in Q1 2025 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Summit Securities Group held 976 shares of CG Oncology worth $69.3K as of Q2 2026.
  • CG Oncology was a new Summit Securities Group position in Q2 2026.
  • CG Oncology made up 0.01% of Summit Securities Group's portfolio in Q2 2026, its #510 holding.
  • Summit Securities Group first reported a position in CG Oncology in Q1 2025 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.